Lyme disease therapeutic - LondonPharma

Drug Profile

Lyme disease therapeutic - LondonPharma

Alternative Names: Artemisinin-based Lyme disease therapeutic - LondonPharma; Lyme disease repurposed therapeutic - LondonPharma

Latest Information Update: 09 Jan 2015

Price : $50

At a glance

  • Originator LondonPharma
  • Class Artemisinins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Lyme disease

Most Recent Events

  • 26 Nov 2014 Phase-I clinical trials in Lyme disease in United Kingdom (Sublingual) before November 2014
  • 13 Jul 2014 Lyme disease therapeutic - LondonPharma is available for licensing as of 17 Dec 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top